human
cytomegaloviru
hcmv
also
known
human
herpesviru
widespread
pathogen
among
human
popul
establish
success
infect
hcmv
depend
uniqu
set
immun
evas
strategi
use
encod
protein
mrna
avoid
compet
innat
adapt
immun
respons
hcmvmediat
infect
recogn
caus
morbid
mortal
immunocompromis
individu
compar
otherwis
healthi
immunocompet
individu
earli
stage
fetu
develop
hcmv
infect
utero
result
dissemin
infect
sever
neurolog
impair
addit
hcmv
infect
also
caus
visual
impair
form
retin
commonli
seen
aid
popul
interestingli
hcmv
capabl
infect
multipl
cell
tissu
type
suggest
abil
interact
divers
array
host
cell
receptor
establish
infect
hcmv
entri
host
cell
extrem
dynam
due
usag
varieti
cellular
entri
receptor
viruscel
interact
shown
depend
cell
type
hcmv
util
multipl
target
cell
receptor
includ
cell
surfac
heparan
sulfat
hs
differ
cellular
integrin
plateletderiv
growth
factor
receptor
alpha
epiderm
growth
factor
receptor
egfr
cellular
entri
flip
side
hcmv
multipl
viral
glycoprotein
includ
gb
go
ghgl
engag
structur
function
unrel
receptor
penetr
cellular
defens
exampl
gb
catalyz
membran
fusion
hcmv
infect
cell
ghglcontain
complex
regul
viral
tropism
interestingli
viral
glycoprotein
contribut
differ
differ
celltyp
wherea
trimer
hcmv
ghglgo
critic
infect
fibroblast
pentam
unit
essenti
viral
entri
epitheli
endotheli
myeloid
cell
distinct
abil
hcmv
util
divers
cell
surfac
receptor
coupl
exploit
multipl
glycoprotein
mediat
entri
pose
special
challeng
drug
discoveri
possibl
sever
bypass
mechan
drug
current
avail
hcmv
treatment
includ
ganciclovir
valganciclovir
foscarnet
cidofovir
fomivirsen
yet
group
carri
number
limit
includ
toxic
aris
prolong
therapi
limit
effect
poor
bioavail
acquir
resist
common
target
discoveri
new
antihcmv
agent
better
efficaci
novel
mechan
action
critic
goal
specif
hcmv
would
benefici
develop
agent
could
simultan
target
multipl
receptor
involv
viral
entri
effect
prevent
bypass
pathway
one
group
receptor
could
target
agent
includ
heparan
sulfat
proteoglycan
first
hcmv
glycoprotein
especi
gb
known
bind
hs
chain
present
cell
surfac
proteoglycan
thu
appropri
competit
molecul
would
expect
reduc
cellular
attach
entri
second
mani
host
cell
surfac
receptor
also
known
bind
hs
growth
factor
receptor
eg
pdgfr
egfr
neuropilin
could
offer
addit
opportun
competit
inhibit
third
inhibitor
viral
entri
could
expect
downstream
consequ
express
viral
immediateearli
gene
whose
product
play
key
role
pathogenesi
hcmv
infect
prevent
reduct
host
immunomodul
fact
literatur
replet
use
heparin
heparan
sulfat
sulfat
polysaccharid
antivir
agent
includ
target
hsv
hiv
other
yet
problem
use
biopolym
extrem
difficult
synthes
character
also
difficult
transform
polysaccharid
scaffold
potenti
druglik
scaffold
would
help
drug
design
develop
effort
time
pursu
nonpolymer
nonsaccharid
mimet
heparinheparan
sulfat
antivir
anticanc
antithrombot
agent
advantag
mimet
fulli
synthet
easili
characteriz
highli
amen
advanc
ration
drug
design
possibl
librari
nonsaccharid
mimet
heparinheparan
sulfat
differ
structur
scaffold
divers
sulfat
group
molecular
size
one
agent
sulfat
pentagalloylglucosid
spgg
distinct
structur
simultan
mimic
mani
differ
sequenc
heparinheparan
sulfat
figur
uniqu
aspect
spgg
globular
structur
theoret
interact
divers
hsbind
protein
fact
earlier
work
spgg
shown
interact
coagul
factor
xia
glycoprotein
gd
two
complet
differ
hsbind
protein
thu
reason
probabl
target
multipl
protein
involv
cellular
entri
hcmv
eg
glycoprotein
gb
pdgfr
egfr
neuropilin
would
higher
spgg
nonsaccharid
mimet
develop
far
although
pleiotrop
ie
abil
bind
multipl
target
disfavor
drug
discoveri
develop
case
hcmv
uniqu
hcmv
reli
multipl
target
gain
access
differ
cell
type
inhibit
pathway
magic
bullet
like
extrem
challeng
time
without
develop
pleiotrop
inhibitor
viru
would
probabl
find
escap
rout
result
suboptim
activ
thu
reason
spgg
like
afford
highest
chanc
success
hcmv
could
becom
use
springboard
develop
first
assess
whether
spgg
toxic
cell
typic
target
hcmv
studi
dosedepend
cell
viabil
util
lactat
dehydrogenas
ldh
assay
surrog
cell
viabil
describ
literatur
briefli
ruptur
plasma
membran
due
apoptosi
necrosi
form
cellular
damag
result
releas
ldh
cell
cultur
supernat
quantifi
nadh
coupl
chromogen
reaction
select
two
differ
cell
line
human
foreskin
fibroblast
neuroepithelioma
cell
sknmc
wellestablish
hcmv
infect
replic
fibroblast
neuron
cell
type
figur
show
viabil
cell
line
function
spgg
concentr
reach
even
incub
period
cell
line
exhibit
essenti
morpholog
chang
mocktreat
control
shown
likewis
neither
cell
line
display
measur
increas
ldh
activ
even
highest
dose
spgg
result
suggest
spgg
display
measur
cytotox
test
cell
line
fact
lethal
concentr
cell
death
like
sever
fold
higher
complet
absenc
increas
ldh
activ
assess
whether
spgg
inhibit
entri
hcmv
sknmc
cell
util
fluorescentlylabel
viru
carri
green
fluoresc
protein
gfp
tag
rapid
quantit
locat
viru
viral
strain
equal
potent
cell
infect
preliminari
studi
perform
assess
infect
sknmc
cell
follow
incub
rt
moi
observ
excel
infect
viral
strain
celltyp
monitor
presenc
multipl
gfp
puncta
aggreg
virion
figur
panel
addit
spgg
result
reduc
number
gfppuncta
cell
type
supplementari
figur
use
imagej
immunolabel
puncta
spgg
treatment
quantifi
compar
mocktreat
cell
line
rel
decreas
gfppuncta
function
spgg
dose
follow
tradit
semilog
relationship
sknmc
cell
figur
panel
c
f
fact
maxim
dose
studi
spgg
treatment
almost
complet
abolish
intern
figur
e
impli
spgg
exhibit
excel
therapeut
window
ratio
respect
two
cell
line
priori
antivir
inhibit
strategi
revolv
competit
antagon
host
cell
entri
reli
chang
gene
express
either
viru
host
howev
evid
gene
express
chang
especi
involv
viral
entri
propag
spread
may
help
better
understand
agent
mechan
action
thu
focus
whether
express
immedi
earli
ie
gene
hcmv
alter
monitor
ie
gene
express
use
wide
character
hcmv
strain
use
cellelisa
assay
figur
control
mocktreat
pb
experi
hcmv
strain
show
robust
express
ie
gene
within
one
hour
incub
host
cell
pretreat
strain
spgg
follow
incub
either
sknmc
cell
show
signific
reduct
express
clear
dosedepend
decreas
ie
express
evid
gave
sknmc
figur
b
puncta
format
best
result
observ
spgg
thu
result
show
spggmediat
interfer
viral
entri
neg
impact
express
viral
gene
probabl
contribut
reduc
viral
infect
studi
first
report
uniqu
heparin
mimet
previous
report
broad
spectrum
antimicrobi
activ
inhibitor
hcmv
earlier
demonstr
spgg
inhibit
hsv
chlamydia
infect
sinc
hsv
chlamydia
known
exploit
heparan
sulfat
earli
stage
host
pathogen
interact
spgg
lower
hcmv
earli
gene
express
surpris
consid
viral
entri
block
first
place
import
point
result
possibl
spgg
could
util
multipl
mechan
antivir
effect
effect
observ
express
import
viral
gene
led
predict
spgg
possibl
function
heparan
sulfat
competitor
reason
spgg
may
possibl
bind
protein
involv
viral
spread
test
hypothesi
morpholog
level
rather
molecular
level
studi
phenomenon
viral
spread
use
plaqu
reduct
assay
assay
use
report
hcmv
strain
atcc
upon
express
xgal
stain
infect
cell
show
blue
foci
plaqu
reduct
assay
consid
gold
standard
antivir
suscept
test
plaqu
reduct
assay
perform
cell
use
spggtreat
pb
mocktreat
report
viru
initi
experi
perform
deduc
optim
concentr
moi
period
infect
wildtyp
viru
detect
foci
aid
studi
celltocel
spread
treatment
mocktreat
hcmv
strain
sevenday
follow
xgal
stain
quantif
bluecolor
infect
foci
magnif
led
highli
reproduc
measur
viral
spread
spgg
use
pretreat
virion
significantli
fewer
foci
observ
day
although
puncta
observ
assay
may
aggreg
multipl
viral
particl
count
number
viral
foci
show
dramat
decreas
comparison
mocktreat
hcmv
figur
especi
import
effect
measur
day
treatment
thu
result
morpholog
level
indic
spgg
also
inhibit
hcmv
celltocel
spread
describ
spgg
highli
sulfat
agent
theoret
bind
sever
hsbind
protein
one
protein
glycoprotein
gb
hcmv
known
heparinbind
protein
fact
design
work
base
expect
spgg
would
bind
one
viral
surfac
glycoprotein
test
expect
studi
whether
spgg
bind
gb
use
dotblot
hybrid
cellelisa
assay
figur
panel
b
show
result
dotblot
presenc
absenc
spgg
concentr
spgg
increas
gb
signal
reduc
untreat
control
although
reduct
signal
intens
lower
concentr
notic
inhibit
robust
observ
profil
viral
entri
express
gene
figur
figur
test
whether
spgg
engag
viral
entri
glycoprotein
gb
studi
chines
hamster
ovari
cell
overexpress
hcmv
gb
cell
surfac
dotblot
hybrid
cellelisa
cell
presenc
spgg
also
led
reduct
gb
signal
intens
comparison
mocktreat
control
figur
togeth
two
independ
experi
two
differ
type
agent
bear
glycoprotein
gb
ie
hcmv
viru
cell
exhibit
almost
equival
result
spgg
result
encourag
like
support
spgg
bind
glycoprotein
gb
hcmv
although
affin
expect
weaker
one
explan
antigb
antibodi
spgg
compet
ideal
site
bind
gb
possibl
competitor
bind
gb
simultan
albeit
partial
competit
manner
result
less
robust
competit
anoth
possibl
spgg
mediat
hcmv
inhibit
multipl
viral
surfac
receptor
one
gb
foundat
expect
spgg
earlier
shown
bind
tightli
glycoprotein
hsv
likewis
spgg
also
inhibit
chlamydia
infect
bind
cell
surfac
receptor
final
potenti
pathway
could
target
spgg
exist
eg
engag
one
host
cell
surfac
receptor
eg
pdgfr
egfr
neuropilin
other
two
latter
like
heparan
sulfat
mimet
known
pleiotrop
entiti
work
demonstr
first
time
concept
small
synthet
sulfat
agent
could
effect
inhibit
hcmv
entri
host
cell
although
previou
work
demonstr
concept
certain
sulfat
natur
unnatur
polysaccharid
eg
dextran
sulfat
pentosan
polysulf
heparin
copolym
acryl
acid
inhibit
hcmv
infect
cell
foundat
activ
base
mimick
polymer
scaffold
heparan
sulfat
shown
critic
hcmv
entri
fact
plausibl
molecular
basi
competit
inhibit
interact
sulfat
polym
viral
glycoprotein
gb
hcmv
specif
competit
inhibit
predict
aris
mimick
structur
certain
heparan
sulfat
eg
sulfat
sulfat
speci
stark
contrast
spgg
much
smaller
sulfat
entiti
perform
mimick
function
excel
potenc
import
smaller
molecular
scaffold
easier
transform
clinic
drug
candid
wherea
polym
difficult
synthes
character
purifi
analyz
monitor
administ
smaller
molecul
exact
opposit
thu
spgg
provid
first
small
molecul
lead
toward
discoveri
antihcmv
drug
major
reason
novelti
behind
discoveri
spgg
possibl
simultan
engag
multipl
receptor
involv
hcmv
entri
host
cell
complex
interact
viral
envelop
glycoprotein
host
cell
receptor
come
play
success
entri
one
reason
natur
seem
engin
multipl
interact
ensur
probabl
success
significantli
reduc
effici
entri
import
simultan
impact
interact
thu
target
interact
speci
inhibit
hcmv
entri
may
yield
clinic
viabl
agent
despit
small
spgg
present
divers
librari
sulfat
speci
could
bind
possibl
heparan
sulfat
bind
receptor
therebi
imped
viral
recognit
appear
case
spgg
bind
glycoprotein
gb
explain
part
inhibit
effect
thu
pleiotrop
spgg
interact
may
key
reason
high
antihcmv
potenc
anoth
reason
behind
excit
spgg
inhibit
immedi
earli
viral
gene
express
two
differ
cell
line
yet
sulfat
biopolym
demonstr
display
phenomenon
find
import
product
immedi
earli
gene
essenti
viral
dna
replic
therefor
spgglike
small
molecul
display
phenomenon
may
offer
novel
strategi
inhibit
hcmv
likewis
reduct
viral
spread
add
valu
inhibitori
role
spgg
import
note
teratogen
toxic
avail
hcmv
antivir
agent
make
treatment
option
earli
develop
markedli
limit
although
spgg
appear
valuabl
term
hcmv
inhibit
import
note
still
mixtur
septasulf
dodecasulf
speci
term
drug
discoveri
still
consider
limit
better
analog
spgg
design
evalu
would
also
import
identifi
receptor
target
engag
spgg
likewis
would
also
import
identifi
whether
certain
viral
entri
pathway
preferenti
target
spgg
develop
strategi
drug
develop
thu
spgg
first
probe
antihcmv
drug
discoveri
summari
result
provid
first
evid
support
pleiotrop
valuabl
approach
discov
antihcmv
agent
project
simultan
block
multipl
step
involv
hcmv
entri
spread
spgg
hold
good
promis
futur
drug
develop
cell
atcc
sknmc
cell
atcc
cell
atcc
purchas
american
type
cultur
collect
atcc
manassa
va
usa
use
vitro
studi
cell
grown
standard
cultur
condit
passag
accord
manufactur
recommend
sknmc
cell
grown
dulbecco
modifi
eagl
medium
dmem
cell
grown
ham
medium
corn
tewksburi
usa
supplement
umgml
penicillinstreptomycin
sigmaaldrich
saint
loui
mo
usa
fetal
bovin
serum
optima
r
system
floweri
branch
ga
usa
hcmv
strain
purchas
atcc
atcc
recombin
deriv
town
strain
carri
express
e
coli
lacz
gene
hcmv
strain
atcc
also
purchas
atcc
hcmv
strain
tandon
lab
deriv
fuse
green
fluoresc
protein
gfp
viral
stock
propag
cell
titer
determin
plaqu
immunofluoresc
assay
result
stock
store
synthesi
spgg
report
earlier
briefli
involv
five
step
start
commerci
avail
raw
materi
culmin
microwavebas
sulfat
reaction
overal
yield
five
step
process
character
spgg
variant
describ
later
report
variant
spgg
use
report
defin
molecular
composit
septa
octa
nona
deca
undeca
dodeca
sulfat
speci
averag
molecular
weight
see
alhorani
et
al
reproduc
synthes
character
use
advanc
lcmsm
method
spgg
variant
studi
variant
far
character
antithrombot
antihsv
antichlamydia
activ
profil
cell
grown
semiconflu
overnight
plate
follow
day
pretreat
spgg
serum
free
media
sfm
h
room
temperatur
rt
agit
cell
infect
treat
untreat
viru
multipl
infect
moi
sfm
h
rock
viral
absorpt
sampl
wash
three
time
phosphat
buffer
salin
pb
addit
overlay
media
dmem
contain
heatinactiv
fb
methyl
cellulos
cytopath
effect
observ
fourseven
day
post
infect
overlay
media
remov
well
wash
three
time
pb
cell
fix
fix
buffer
paraformaldehyd
glutaraldehyd
pb
min
wash
three
time
pb
incub
permeabil
buffer
mm
deoxychol
nonidet
pb
min
cell
incub
substrat
solut
contain
xgal
thermo
fisher
waltham
usa
bluestain
infect
cell
count
magnif
invert
microscop
cellular
toxic
spgg
evalu
h
use
lactat
dehydrogenas
ldh
releas
indic
damag
plasma
membran
assay
perform
use
cytotox
assay
kit
thermo
fisher
waltham
usa
previous
describ
sknmc
cell
grown
semiconflu
overnight
black
opaqu
plate
follow
day
preincub
differ
dilut
spgg
h
agit
cell
infect
moi
treat
untreat
viru
h
rt
infect
media
replac
sfm
incub
addit
h
standard
condit
sampl
fix
min
methanol
wash
three
time
trisbuff
salin
tb
block
h
proteinfre
block
buffer
thermo
fisher
waltham
usa
sampl
incub
overnight
mous
monoclon
antibodi
immedi
earli
gene
virusi
taneytown
md
usa
cat
dilut
block
buffer
next
sampl
wash
three
time
wash
buffer
tween
tb
incub
h
rt
goat
antimous
igg
hl
peroxidaseconjug
secondari
antibodi
thermo
fisher
waltham
usa
dilut
wash
buffer
sampl
wash
time
wash
buffer
super
signal
elisa
femto
substrat
thermo
fisher
waltham
usa
ad
total
luminesc
analyz
use
micropl
luminomet
beckman
dtx
sknmc
cell
seed
cover
glass
plate
grown
confluenc
overnight
viru
strain
preincub
dilut
spgg
h
agit
cell
infect
moi
treat
untreat
viru
h
rt
infect
media
replac
sfm
incub
addit
h
standard
condit
sampl
wash
three
time
pb
fix
min
wash
addit
three
time
sampl
incub
overnight
antigfp
mous
secondari
antibodi
thermo
fisher
waltham
usa
dilut
block
buffer
sampl
wash
three
time
pb
incub
normal
goat
serum
dilut
wash
buffer
overnight
sampl
wash
time
pb
incub
goat
antimous
igg
alexa
fluor
thermo
fisher
waltham
usa
dilut
wash
buffer
h
rt
sampl
wash
three
time
pb
incub
phalloidin
thermo
fisher
waltham
usa
dilut
block
buffer
min
humid
chamber
sampl
wash
two
time
pb
triton
mount
slide
hardset
mount
media
dapi
vector
laboratori
burlingam
ca
usa
slide
imag
use
nikon
confoc
microscop
imag
process
use
imagej
version
nation
institut
health
usa
gfpposit
puncta
enumer
random
view
per
slide
cell
plate
plate
grown
confluenc
follow
day
cmv
gb
plasmid
pccmvgb
tandon
lab
transfect
cell
use
lipofectamin
thermofish
waltham
usa
incub
overnight
transfect
media
replac
complet
media
allow
cell
recoveri
follow
transfect
cell
incub
dilut
spgg
h
sfm
standard
condit
cell
wash
tb
fix
methanol
five
minut
wash
cellelisa
protocol
describ
previous
follow
use
monoclon
antibodi
hcmv
gb
acri
rockvil
md
usa
cat
goat
antimous
peroxidas
conjug
secondari
antibodi
dilut
thermofish
waltham
usa
final
wash
plate
done
three
time
tbst
tmb
substrat
pierc
biotechnolog
rockford
il
usa
ad
reaction
stop
enzymat
activ
measur
od
nm
micropl
photomet
thermo
scientif
multiskan
fc
hcmv
strain
preincub
dilut
spgg
h
agit
rt
follow
incub
spot
contain
pfu
spgg
appli
nitrocellulos
membran
biorad
laboratori
hercul
ca
spot
dri
membran
block
proteinfre
block
buffer
thermofish
waltham
usa
h
standard
elisa
protocol
previous
describ
follow
use
monoclon
antibodi
hcmv
gb
acri
goat
antimous
peroxidas
conjug
secondari
antibodi
dilut
thermofish
final
wash
blot
incub
aec
stain
solut
sigmaaldrich
st
loui
mo
usa
min
rins
water
imag
intens
signal
quantifi
use
imagej
gel
analysi
function
calcul
plot
area
peak
experi
perform
triplic
unless
otherwis
state
confirm
consist
result
student
ttest
anova
use
analyz
data
pvalu
less
consid
statist
signific
control
treatment
group
imagej
use
enumer
gfp
signal
random
section
infect
cell
confoc
microscopi
also
use
estim
rel
densiti
size
sampl
dot
blot
